跳至主要内容
临床试验/NCT01481025
NCT01481025Unknown3 期

Phase 3 Study - Efficacy and Tolerance for the Mixture of Dry Extracts Black Cohosh and Saint John's Worth Versus Isolated Black Cohosh Extract for the Climacteric Symptoms' Control

Phytopharm Consulting Brazil1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
发起方
入组人数
210
试验地点
1
主要终点
Menopause Rating Scale

研究概览

简要总结

Climacteric Complains bring to women many problems for living a normal life - hot flashes, irritation are 2 of many problems and the mixture of those 2 plant extract must bring a new horizon for this part of time.

详细描述

2 herbal extracts used in general alone will be running together for the best climacteric women on quality of life.

The investigators will test the mixture already in the market as GynoPlus and RemifeminPlus, but as each extract has its own particularities the investigators will try CIM/HIP as a unique formulation versus Clifemin® as control and Aplause® as comparator.

This protocol was performed for the best of our volunteers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
45 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Climacteric women 45-60 years old - pre and postmenopausal
  • Climacteric complains for at least 3 months
  • No treatments for at least 2 months
  • MRS score 0.4 or more for at least 3 items
  • Hamilton's Scale score from 15-23

排除标准

  • Hormon Therapy or any other for the last 3 months
  • Antidepressive and Hypnotic medication for the last 3 months
  • Sever illness (cardiac, hepatic, renal, digestive or metabolic) or TSH alteration
  • History for allergies and hipersensitivity to any component of the drugs formulations
  • No knowledge for reading or writing
  • Suicide risk

研究组 & 干预措施

Cimicifuga+Hiperico

Experimental

80 + 450 mg / tablet

干预措施: Cimicifuga + Hiperico (Drug)

Cimicifuga Herbarium

Active Comparator

80 mg / caps

干预措施: Cimicifuga Herbarium (Drug)

Aplause®

Active Comparator

20 mg / tablet

干预措施: Aplause® (Drug)

结局指标

主要结局

Menopause Rating Scale

时间窗: 8 months

Climacteric Symptoms Evaluation - "MRS - Menopause Rating Scale\*

次要结局

  • Hamilton's Depression Scale(8 months)
  • WHOQOL(8 months)
  • Health Numbers(8 months (T-2 to T6))

研究者

发起方
Phytopharm Consulting Brazil
申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验